

# SURINAME

## Cutaneous and mucosal Leishmaniasis 2018

Incidence  
(100,000 pop.) **137.1**  
Transmission **Very Intense**  
Triennium Leishmaniasis  
Composite Indicator  
(TLCIc 2016-2018)



### Occurrence

# 118

NEW CASES

118 unspecified  
(100%)

### TLCIc triennium (2016-2018)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. ©WHO 2015. All rights reserved.



#### AGE GROUP

2.5% < 5 Y/O  
0.9% ≥ 5 < 10 Y/O  
96.6% > 10 Y/O

**3.4%** children  
under 10 years old



#### GENDER

89% Male  
11% Female

**86.4%** men over 10  
years old



#### CROSS-BORDER

Shares borders with  
**03** countries

Cross-border  
information **NOT**  
available at SisLeish



#### SURVEILLANCE AND CONTROL

**15.9%** of the population  
in transmission areas

**Decrease** of the CL % in  
children under 10 Y/O  
compared to the previous  
year (Targets of the 2017-  
2022 Plan of Action)



#### LEISHMANIA SPECIES

Information  
**NOT** available at  
SisLeish



#### LUTZOMYIA VECTORS

Information  
**NOT** available  
at SisLeish



#### PATIENT ASSISTANCE

Laboratory confirmation:  
**94%**

Cura clínica: **100%**

% of cured patients among  
the treated: **N/I**



#### AVAILABLE MEDICINE

Pentamidine  
isethionate

#### Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health -  
National Leishmaniasis Programs

Accessed on: 01 November 2019.

N/I: No information available; Y/O: years old